News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oculus Innovative Sciences, Inc. (OCLS) Announces Results From Study of Microcyn® Technology-Based Atrapro™ Antipruritic Hydrogel Used in Combination With Neosalus® Cream in Treatment of Atopic Dermatitis



10/9/2012 9:22:17 AM

PETALUMA, Calif., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced results of a multicenter, prospective and open-label pilot study in which Microcyn® Technology-based Atrapro™ Antipruritic Hydrogel was evaluated in combination with Neosalus® Cream in the treatment of atopic dermatitis. The two products are frequently marketed as a comprehensive treatment regimen for skin dermatoses including atopic dermatitis.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES